Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Sleep apnea stories

Aug 31, 2026

Sleep apnea pill reduces breathing events by 44% in phase 3 trial

A once-nightly pill cut breathing interruptions by approximately 44% in a major phase 3 sleep apnea trial, while improving oxygen levels and disease severity by strengthening airway muscles.

Aug 31, 2026·2 sources
00

Top claims

  • ▪The most frequently reported side effects of AD109 in the phase 3 trial were dry mouth, nausea, insomnia, and difficulty urinating
  • ▪Participants receiving a placebo in the SynAIRgy trial experienced an 18% reduction in their apnea-hypoxia index, compared to the 44% reduction seen in the AD109 group
  • ▪Continuous Positive Airway Pressure remains the gold standard treatment for obstructive sleep apnea, but many patients remain untreated or undertreated due to difficulty tolerating the device

Subtopics

Sleep & circadian rhythmSleep medicationsClinical trials

Related timelines

AI Data Center Gold Rush

76 stories

Payments

102 stories

Venture capital funding

93 stories

Congress

104 stories

Crypto hacks

83 stories